Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus Etoposide in Advanced NSCLC
NCT02733107Phase 2Unknown
- Sponsor
- Army Medical University
- Start
- Mar 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Army Medical University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02733107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02733107.